Rezultati pretraživanja
  1. 20. sij

    Didn't make it to last Nov, don't worry!! on 23rd Jan at 18:15 Dr Fatima Cardoso & will look at the highlights from what was a very successful ESO-ESMO Advanced Breast Cancer Fifth International Consensus Conference

  2. 2. pro 2019.

    If you missed or would like to take a look at a presentation you particularly enjoyed then you can view all the available presentations here

  3. 20. stu 2019.

    Dear Colleagues, Fresh from our colleague 👩‍⚕️from 🇮🇹speaks to 🚨about her presentation at ABC5 on 2nd line T-DM1 after dual HER2 blockade in advanced ‼️ Best, 🌍

  4. 19. stu 2019.

    Honoured to have been nominated but now I’ve won the catagory! Thank you so much & am looking forward to the event next week!

  5. We were glad to participate in the 2019 conference in Portugal. Many new things learned from the impressive lineup of speakers & facilitators. Thanks to and for putting together an impactful programme.

  6. 17. stu 2019.

    Overall survival needs to be measured in design. Strongly fought by Pharma because clinical benefits may not prove statistical significant. People with metastatic cancer want to live longer with quality of life. 👇🏻👇🏻👇🏻

  7. 17. stu 2019.

    A great pleasure to have caught up w/our amazing🙌 🚨colleague Kelly Shanahan at who talked to us about the importance of the collaboration and exchange between Oncologists, Patient advocates and Oncology Nurses‼️ We are ALL 🌎

  8. 16. stu 2019.

    It’s been a wonderful conference- ! Just hoping to get my voice back by !! 🤧

  9. 16. stu 2019.

    ABC5 consensus guidelines session this morning first 2 hours have been dedicated guidelines for patients with ER+, HER2 - tumors. Back 6 years ago the votes for this group took <1/2 hour. What an improvement in terms of treatment options for your patients!!!

  10. 16. stu 2019.

    Such an honour to be part of the panel of the ABC 5 consensus meeting

  11. 16. stu 2019.

    . and ESMO International Consensus Guidelines for Advanced session starting now at

  12. 15. stu 2019.

    How much time have I got, Doc? "Best, Worst, and Typical Cancer Survival"--a proposed new framework for estimates. Katherine O'Brien, a patient advocate w/ metastatic breast cancer, reports from conference,

  13. 15. stu 2019.

    A great and simple idea for estimating cancer survival -- excellent first contribution to from journalist Katherine O'Brien

  14. 15. stu 2019.

    An underlining message from several speakers at today: we are going to change how we define HER2 in breast cancer in the next few years, starting from thinking of HER2-low beyond HER2 positive/negative!

  15. Experience the artistic campaign and learn more about the interpretative work created by at to give a voice to those living with .

  16. 15. stu 2019.

    Lesley Fallowfield asked a great question at - should pharma be mandated to spend 0.00000001% (or something of that order!) on research into drugs that treat the many side effects of the drugs they develop for MBC.

  17. 15. stu 2019.

    Do you think new biomarkers will change the way we classify breast cancer in the near future? Prof with his great presentation at conference made me think this is likely to happen soon, expecially in HER2-positive breast cancer.

  18. 15. stu 2019.

    Dr. Benedetta Conte ⁦⁩ presenting at ABC ⁦⁩ conference in Lisbon the results of GIM14 TDM1 after trastu-pertuzumab in HER2+ disease Great job!

  19. such an important point and without including patients in clinical trial design, we may not be designing trials to best answer the questions and address issues that are most important to patients

  20. The Invisible Woman installation combines the power of visual interaction with patient storytelling to bring into focus the everyday reality of women living with .

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.